SecBot SecBot
8-K ·Filed Apr 22, 2026

INDP

Indaptus Therapeutics, Inc.
NEUTRAL
Impact 3/10
Horizonweeks Processed6mo ago SEC0001493152-26-018608
8-K context-dependent: Items 5.02
Actionable Insight • Neutral

Monitor upcoming 10-Q filing for any changes in financial guidance or operations following the board refresh. The addition of an audit committee financial expert may improve financial oversight.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$3.15
T+0 close · Apr 22, 2026 · via day close
Latest settled
−21.90%
T+60 · $2.46
Vs SPY
−26.92%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 23 $3.15entry
  2. T+1 · 7mo ago +4.76%α +3.98% · $3.30
  3. T+5 · 7mo ago −7.30%α −8.78% · $2.92
  4. T+20 · 6mo ago −60.95%α −65.59% · $1.23
  5. T+60 · 4mo ago −21.90%α −26.92% · $2.46
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Indaptus Therapeutics appointed two new independent directors, Tim Ruan and Dr. Yi Zhang, while Matthew McMurdo resigned. The company also formalized indemnification agreements with the new directors. These are routine governance changes with no immediate financial impact.

Key Facts

  • Appointed Tim Ruan and Dr. Yi Zhang as independent directors effective April 22, 2026
  • Matthew McMurdo resigned as director with no disclosed disagreements
  • Both new directors received annual $30,000 retainers and indemnification agreements
  • Ruan appointed to Audit Committee and qualifies as audit committee financial expert
  • Zhang appointed to Nominating Committee

Financial Impact

Minimal annual cost of $60,000 in director compensation

operating expensesgeneral and administrative expenses

Risk Factors

  • Potential director turnover instability with one resignation concurrent with new appointments
  • Limited biotech governance experience of new directors despite strong financial and IP backgrounds

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001493152-26-018608
Exhibit: ex10-1.htm0001493152-26-018608
Document: form8-k.htm0001493152-26-018608
Document: 0001493152-26-018608-index-headers.html0001493152-26-018608
Document: 0001493152-26-018608-index.html0001493152-26-018608
Document: 0001493152-26-018608.txt0001493152-26-018608

Track record

20 reports on INDP

Performance horizon

4 of 9 bullish or bearish reports moved the stock their way by T+20. Best: +59.35% at T+20 after the Jul 20, 2026 report. 6 of 10 went positive at some point.

Filters
  1. Nov 13, 20263d ago Press Release Neutral 4/10 Entry $3.17 Now $3.45 +8.83% settles Dec 15
  2. Oct 22, 202625d ago SC 13D/A Neutral 4/10 Entry $3.16 Now $3.45 +9.18% settles Nov 20
  3. Oct 22, 202625d ago SC 13D/A Neutral 3/10 Entry $3.16 Now $3.45 +9.18% settles Nov 20
  4. Oct 22, 202625d ago SC 13D/A Neutral 4/10 Entry $3.16 Now $3.45 +9.18% settles Nov 20
  5. Oct 21, 202626d ago SC 13D/A Neutral 4/10 Entry $2.99 Now $3.45 +15.38% settles Nov 19
  6. Oct 20, 202627d ago 8-K Bearish 6/10 Entry $3.16 Now $3.45 −9.18% settles Nov 18
  7. Sep 30, 20266w ago 8-K Neutral 3/10 Entry $2.30 to $3.31 Now $3.45 +50.00% ▲ +43.70% +42.43% vs SPY
  8. Sep 9, 20269w ago 8-K Bearish 7/10 Entry $2.56 to $2.37 Now $3.45 −34.77% ▲ +7.42% +9.55% vs SPY
  9. Sep 4, 202610w ago 424B5 Bearish 6/10 Entry $1.85 to $2.59 Now $3.45 −86.49% ▼ −40.00% −38.29% vs SPY
  10. Sep 1, 202610w ago 8-K Bearish 5/10 Entry $1.13 to $2.32 Now $3.45 −205.31% ▼ −104.87% −103.69% vs SPY
Showing 10 of 20

US Market Status

Market Closed · Opens in 6h 35m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 23, 2026